ACTG Launches Second HIV Cure Clinical Trial in Africa [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the ACACIA study ( A ntiretrovirals C ombined with A ntibodies for HIV-1 C ure in A frica), also known as A5417. ACACIA is a phase 2, double-blind, randomized study evaluating the safety and virologic and immunologic effects of the two long-acting broadly neutralizing antibodies (bNAbs) 3BNC117-LS and 10-1074-LS when given at the start of antiretroviral therapy (ART) to adults living with HIV in four African countries. This study complements ACTG's PAUSE study, which is evaluating two very similar bNAbs among people living with HIV who have been virally suppressed on ART and enrolled the first participant in June 2024. Participants in ACACIA and PAUSE will undergo an analytic treatment interruption (ATI) – a closely monitored pause in ART. ATIs are an integral part of HIV cure trials, because they enable researchers to
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic DermographismGlobeNewswire
- Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.MarketBeat
- Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Celldex Announces Appointment of Teri Lawver as Chief Commercial OfficerGlobeNewswire
- Celldex to Present at Upcoming Investor ConferencesGlobeNewswire
CLDX
Earnings
- 11/10/25 - Miss
CLDX
Sec Filings
- 12/8/25 - Form 4
- 12/4/25 - Form 144
- 11/17/25 - Form 4
- CLDX's page on the SEC website